Products Brodalumab was approved in Japan in 2016 (Lumicef) and in the United States and EU in 2017 as a solution for injection (Siliq, Kyntheum). Structure and properties Brodalumab is an IgG2κ monoclonal antibody with a molecular weight of 144 kDa, consisting of 1312 amino acids. It is produced by biotechnological methods. Effects Brodalumab (ATC … Brodalumab
Products Ixekizumab was approved in the United States, the EU, and many countries in 2016 as a solution for injection in a prefilled pen and syringe (Taltz). Structure and properties Ixekizumab is a humanized IgG4 monoclonal antibody with a molecular mass of 146 kDa produced by biotechnological methods. Effects Ixekizumab (ATC L04AC13) has immunosuppressive and … Ixekizumab
Symptoms Psoriasis is a chronic inflammatory, benign, and noninfectious skin disease. It manifests as symmetrical (bilateral), sharply demarcated, bright red, dry, raised plaques covered by silvery scales. Typically affected areas are the elbows, knees, and scalp. Itching, a burning sensation and pain are other symptoms, and scratching further aggravates the condition. Psoriasis can also affect … Psoriasis Causes and Treatment
Products The first therapeutic monoclonal antibody was approved in 1986. Muromonab-CD3 (Orthoclone OKT3) binds to the CD3 receptor on T cells and has been used in transplantation medicine. Numerous drugs containing antibodies are now available. A selection of active substances can be found at the end of this article. These are expensive drugs. For example, … Monoclonal Antibodies